Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
- Main trialPhase 2
- “This study aims to evaluate the efficacy and safety of lesigercept in approximately 150 participants with CSU. By enrolling participants with an inadequate response to H1-antihistamines, including those previously treated with omalizumab, this study is expected to provide evidence for the clinical utility of lesigercept and to further characterize its benefit-risk profile in the target participant population.”In the company’s words, NCT07415551 on ClinicalTrials.gov
Other drugs for Allergic Diseases
- RemibrutinibNovartis · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 3
- JYB1904Jemincare · Phase 3
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- LP-003Longbio Pharma · Phase 3
- BarzolvolimabCelldex Therapeutics · Phase 3
Coming up1
- 19 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 19 Jun 2027 | Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026